Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05601752 · ClinicalTrials.gov registry record · Phase 2
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
A Phase 2 study of Ovarian Cancer, sponsored by Uswm CT.
- Active
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 20
- Study locations
NCT05601752 is a Phase 2 study of Ovarian Cancer that is active but no longer recruiting, run by Uswm CT. The registered enrollment target is 66 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05601752, a Phase 2 study of Ovarian Cancer, is active but no longer recruiting, sponsored by Uswm CT.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.
Conditions Studied
Interventions
- GENETIC Autologous genetically modified ADP-A2M4CD8 cells
- COMBINATION_PRODUCT Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
Study Locations (20)
Other
- Centre Leon-Berard - Lyon
- Institut de Cancerologie de Strasbourg - Strasbourg
- Institut Gustave Roussy - Villejuif
- Vall d'Hebron Unversity Hospital - Barcelona
- Clinica Universidad de Navarra - Madrid
- Hospital Universitario Ramón y Cajal - Madrid
- Hospital Universitario Fundación Jiménez Díaz - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- Centro Oncologico Clara Campal - Madrid
Arizona
- Honor Health - Scottsdale
California
- City of Hope - Duarte
Georgia
- Augusta University - Augusta
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- Rutgers Cancer Institute of NJ - New Brunswick
Ohio
- Cleveland Clinic Foundation - Cleveland
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-06-26 |
| Est. Completion | 2026-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05601752
The ClinicalTrials.gov registry entry for NCT05601752 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Uswm CT, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Autologous genetically modified ADP-A2M4CD8 cells is the first listed.
NCT05601752 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05601752 about?
NCT05601752 is a clinical study titled "ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)". This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.
What is the current status of trial NCT05601752?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2023-06-26. Estimated completion is 2026-08-12.
What conditions does trial NCT05601752 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT05601752?
The interventions under investigation include: Autologous genetically modified ADP-A2M4CD8 cells (GENETIC), Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05601752?
This trial is sponsored by Uswm CT, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05601752 being conducted?
This trial has 20 study locations across Arizona, California, Georgia, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.